The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Wednesday broker round-up

Wed, 14th Apr 2021 13:07

(Sharecast News) - Gamesys Group: Canaccord downgrades to hold with a target price of 1,878p.



Watkin Jones: Berenberg reiterates buy with a target price of 280p.

Boohoo Group: Berenberg reiterates buy with a target price of 460p.

Quixant: Canaccord reiterates buy with a target price of 200p.

Babcock: JP Morgan upgrades to overweight with a target price of 350p.

Restaurant Group: JP Morgan downgrades to neutral with a target price of 120p.

Just Eat: Barclays reiterates overweight with a target price of 121p.

IQE: Deutsche Bank reiterates buy with a target price of 80p.

AstraZeneca: Deutsche Bank reiterates buy with a target price of 10,200p.

XP Power: Liberum reiterates buy with a target price of 6,500p.

British Land: Liberum reiterates hold with a target price of 500p.

Qinetiq: Numis reiterates buy with a target price of 400p.

Related Shares

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.